CANF Stock Forecast & Price Target

Can-Fite Biofarma Ltd is advancing its clinical-stage drug candidates, notably Piclidenoson and Namodenoson, with projected risk-adjusted global sales growing from ~$3 million to $126 million between 2027 and 2031, demonstrating a strong potential revenue trajectory. The company has secured FDA and EMA alignment on its Phase 3 trial protocols, indicating confidence in the efficacy and safety of its therapeutic candidates, particularly in the competitive oral psoriasis market and for liver cancer treatment. Remarkably, a patient treated with Namodenoson has shown a complete response and an overall survival of nine years, underscoring the drug's clinical benefits and strengthening the company's long-term growth prospects.

Can Fite Biofarma Ltd faces significant challenges that contribute to a negative outlook on its financial prospects, primarily due to potential difficulties in product commercialization and regulatory approval processes that could hinder revenue generation. The company reported a net loss of $4.9 million in the first half of 2025, with projections indicating a further loss of $10 million for the entire year, signaling ongoing financial instability. Additionally, factors such as competitive pressures, patient enrollment delays in clinical trials, and potential issues with intellectual property protection further exacerbate concerns about Can Fite's ability to capitalize on its product pipeline, including its drug candidates Piclidenoson and Namodenoson.